Michael Cheng, MD, BA

Walmsley CS, Jonsson P, Cheng ML, McBride S, Kaeser C, Vargas HA, Laudone V, Taylor BS, Kappagantula R, Baez P, Richards AL, Noronha AM, Perera D, Berger M, Solit DB, Iacobuzio-Donahue CA, Scher HI, Donoghue MTA, Abida W, Schram AM. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. NPJ precision oncology 2024. PMID: 38355834

Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research 2024. PMID: 38276989

Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. Initial chemotherapy for locally advanced and metastatic NUT carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023. PMID: 38154515

Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J, GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. The New England journal of medicine 2023. PMID: 37611121

Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023. PMID: 37097610

Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO precision oncology 2023. PMID: 37384867

Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, J?nne PA. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO precision oncology 2022. PMID: 36455195

Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, ?nsal-Ka?maz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers 2022. PMID: 36077617

Cheng ML, Thomas V, Vaz N, Hammer MM, Nishino M, Vargas SO, Khalil HA. Lipid pneumonia associated with mineral oil use presenting as fluorine-18-fluorodeoxy-D-glucose-avid lung mass. JTCVS techniques 2022. PMID: 36276695

French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. Report of the First International Symposium on NUT Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2022. PMID: 35417004

Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. JTO clinical and research reports 2022. PMID: 35815322

Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, J?nne PA. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO precision oncology 2021. PMID: 34994618

Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021. PMID: 33845210

Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, Srinivasan P, Huberman K, Meng F, Jing X, Patel J, Hasan M, Johnson I, Gedvilaite E, Houck-Loomis B, Socci ND, Selcuklu SD, Seshan VE, Zhang H, Chakravarty D, Zehir A, Benayed R, Arcila M, Ladanyi M, Funt SA, Feldman DR, Li BT, Razavi P, Rosenberg J, Bajorin D, Iyer G, Abida W, Scher HI, Rathkopf D, Viale A, Berger MF, Solit DB. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome medicine 2021. PMID: 34059130

Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). Journal for immunotherapy of cancer 2021. PMID: 33771889

Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, J?nne PA, Oxnard GR, Paweletz CP. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO precision oncology 2021. PMID: 34250387

Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA: a cancer journal for clinicians 2020. PMID: 33165928

Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, Bromberg M, Ling L, Selcuklu SD, Arcila ME, Tsui DWY, Zehir A, Viale A, Berger MF, Bosl GJ, Sheinfeld J, Van Allen E, Taylor BS, Al-Ahmadie H, Solit DB, Feldman DR. Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO precision oncology 2020. PMID: 33163850

Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, J?nne PA, Oxnard GR. Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO precision oncology 2020. PMID: 33015530

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32332016

Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma research 2020. PMID: 31425479

Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, J?nne PA, Kuo FC, Oxnard GR, Sholl LM. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung cancer (Amsterdam, Netherlands) 2019. PMID: 31855703

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Tumour lineage shapes BRCA-mediated phenotypes. Nature 2019. PMID: 31292550

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology 2019. PMID: 30589920

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell 2018. PMID: 30205045

Cheng ML, Oxnard GR. Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC? Clinical cancer research : an official journal of the American Association for Cancer Research 2018. PMID: 30190372

Cheng ML, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature reviews. Cancer 2018. PMID: 30030494

Cheng ML, Iyer G. Novel biomarkers in bladder cancer. Urologic oncology 2018. PMID: 29472156

Cheng ML, Solit DB. Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Annals of internal medicine 2018. PMID: 29310131

Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer epidemiology 2015. PMID: 25662402

Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Current treatment options in oncology 2014. PMID: 24402184

Cheng ML, Fong L. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Frontiers in oncology 2014. PMID: 24432249

Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy 2012. PMID: 23199349

Cheng ML, Leibowitz M, Ha E. Coccidioidal endophthalmitis in immunocompetent person, California, USA. Emerging infectious diseases 2012. PMID: 22608196